PPARγ agonists and coronary atherosclerosis

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Atherosclerosis Reports

• Publication date

  2008-04-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11883-008-0020-4
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.

  2007cited by this paper
• Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007cited by this paper
• Triglyceride-Rich Lipoproteins Prime Aortic Endothelium for an Enhanced Inflammatory Response to Tumor Necrosis Factor-α

  2007cited by this paper
• [Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43].

  2007cited by this paper
• Cardiovascular safety of rosiglitazone.

  2007cited by this paper
• The PPAR regulatory system in cardiac physiology and disease.

  2007cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  2006cited by this paper
• Adiposity of the Heart*, Revisited

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• PPARγ and human metabolic disease

  2006cited by this paper
• Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels.

  2005cited by this paper
• Nuclear Factor &kgr;B Signaling in Atherogenesis

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

  2005cited by this paper
• Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol

  2005cited by this paper
• Molecular mechanisms of insulin resistance that impact cardiovascular biology.

  2004cited by this paper
• Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.

  2004cited by this paper
• Liver glucokinase can be activated by peroxisome proliferator-activated receptor-gamma.

  2004cited by this paper
• Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.

  2003influential reference
• Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

  2003cited by this paper
• Muscle-specific Pparg deletion causes insulin resistance

  2003cited by this paper
• Peroxisome Proliferator-Activated Receptor &ggr; Ligands Increase Release of Nitric Oxide From Endothelial Cells

  2003cited by this paper
• Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study.

  2003cited by this paper
• Myocardial triglycerides and systolic function in humans: In vivo evaluation by localized proton spectroscopy and cardiac imaging

  2003cited by this paper
• Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.

  2003cited by this paper
• Antiinflammatory effects of ω-3 fatty acids vary at different stages of inflammation

  2003cited by this paper
• Olive oil feeding up-regulates uncoupling protein genes in rat brown adipose tissue and skeletal muscle.

  2002cited by this paper
• Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha.

  2002cited by this paper
• Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.

  2002influential reference
• Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation.

  2002cited by this paper
• Emerging roles of PPARS in inflammation and immunity

  2002cited by this paper
• Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice

  2001cited by this paper
• Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice: Pleiotropic Effects on CD36 Expression and HDL

  2001cited by this paper
• Peroxisome proliferator-activated receptors in inflammation control.

  2001cited by this paper
• Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

  2000cited by this paper
• Peroxisome Proliferator-Activated Receptor γ Activators Downregulate Angiotensin II Type 1 Receptor in Vascular Smooth Muscle Cells

  2000cited by this paper
• Troglitazone inhibits angiotensin II‐induced extracellular signal‐regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells

  1999cited by this paper
• Insulin signaling in the arterial wall.

  1999cited by this paper
• Very Low-Density Lipoprotein Activates Nuclear Factor-κB in Endothelial Cells

  1999cited by this paper
• Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1*

  1999cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.

  1998cited by this paper
• Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer ( PPAR g Agonist ) Action

  1998cited by this paper
• Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients

  1997influential reference
• Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

  1997cited by this paper
• Inhibition of phagocyte-endothelium interactions by oxidized fatty acids: a natural anti-inflammatory mechanism?

  1996cited by this paper
• Fatty acid activation of peroxisome proliferator-activated receptor (PPAR).

  1995cited by this paper
• Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor.

  1993cited by this paper
• The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene.

  1992cited by this paper
• Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis.

  1973cited by this paper

• Development of surface modified nanoparticles of curcumin for topical treatment of diabetic retinopathy: In vitro, ex vivo and in vivo investigation

  2022cites this paper
• Pathological role of advanced glycation end products (AGEs) and their receptor axis in atrial fibrillation.

  2019cites this paper
• Identification of a novel selective PPARγ ligand with a unique binding mode and improved therapeutic profile in vitro

  2017cites this paper
• Role of Peroxisome Proliferator Activator Receptor ó in Diabetic Retinopathy Pathophysiology

  2012cites this paper
• Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR‐γ‐related pharmacology

  2012cites this paper
• Identification and Mechanism of 10-Carbon Fatty Acid as Modulating Ligand of Peroxisome Proliferator-activated Receptors*

  2011cites this paper
• Osteogenic differentiation of mesenchymal stem cells is preserved by partial, but not full peroxisome proliferator-activated receptor-γ agonist.

  2011cites this paper
• Obesity and endothelial dysfunction : mechanisms, method development and interventions.

  2010cites this paper
• Anticancer Role of PPARγ Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes

  2010cites this paper
• PPARs and Anticancer Therapies

  2010cites this paper
• Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.

  2009cites this paper